Condition: Advanced Hepatocellular Carcinoma (HCC) · Sponsor: Sun Yat-sen University
The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.
This description comes directly from the study's public registry record.
Lujun Shen, M.D. · 86-13560365452 · shenlj@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Gansu Province Cancer Hospital | Lanzhou, Gansu, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06737913